Evidence map›Paper›PMID 42473860›Full record

ArticleNanomedicine (London, England)2026

Longitudinally cultured precision cut lung slices as a predictive

Ara Sargsian, Hermon Girmatsion, Vincent Lenders, Ghesquière Bart, Stefaan J Soenen, Bella B Manshian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ara SargsianDepartment of Imaging and Pathology, NanoHealth and Optical Imaging Group, KU Leuven, Belgium.ORCID 0000-0001-6737-649X
Hermon GirmatsionDepartment of Imaging and Pathology, NanoHealth and Optical Imaging Group, KU Leuven, Belgium.ORCID 0009-0005-6987-6187
Vincent LendersDepartment of Imaging and Pathology, Translational Cell and Tissue Research Unit, KU Leuven, Belgium.
Ghesquière BartDepartment of Cellular and Molecular Medicine, Metabolomics Expertise Center, KU Leuven, Belgium.ORCID 0000-0003-1547-1705
Stefaan J SoenenDepartment of Imaging and Pathology, NanoHealth and Optical Imaging Group, KU Leuven, Belgium.ORCID 0000-0003-2390-3133
Bella B ManshianDepartment of Imaging and Pathology, NanoHealth and Optical Imaging Group, KU Leuven, Belgium.ORCID 0000-0002-3402-3927

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimExploring alternatives to MATERIAL AND

methodsUsing Paclitaxel as a benchmark drug and a therapeutically promising silver nanoparticles in combination with immunotherapy, we conducted a pioneering comparative analysis of its therapeutic effects on PCLS against traditional in vivo models.

resultsRevealed that PCLS closely mimics

conclusionThis direct comparison not only confirms the utility of PCLS in simulating real-world outcomes but also emphasizes its potential in reducing animal testing. By providing a reliable, ethical, and efficient alternative for lung cancer studies, PCLS could significantly enhance preclinical research and drug development, marking a critical step toward more humane and representative scientific investigations.

Indexed as

LungLung NeoplasmsMetal NanoparticlesAnimalsCell Line, TumorHumansMicePaclitaxelSilverPaclitaxelSilvercancer modelsex vivo modelsnanoparticlespersonalized medicinePrecision cut tissue slices

Identifiers

PMID42473860
PMCPMC13505445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.